Journal article icon

Journal article

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Abstract:

Background: Dysregulated inflammation is associated with poor outcomes in COVID-19. We aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating factor inhibitor) and infliximab (a tumour necrosis factor inhibitor) in hospitalised patients with COVID-19, to prioritise agents for phase 3 trials.

Methods: In this randomised, multicentre, multi-arm, multistage, parallel-group, open-label, adaptive, phase 2, proof-of-concep...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/s2213-2600(21)00460-4

Authors


Expand authors...

Contributors

Role:
Contributor
Publisher:
Elsevier Publisher's website
Journal:
Lancet Respiratory Medicine Journal website
Volume:
10
Issue:
3
Pages:
255-266
Publication date:
2021-12-16
Acceptance date:
2021-10-12
DOI:
ISSN:
2213-2600
Language:
English
Keywords:
Pubs id:
1225685
Local pid:
pubs:1225685
Deposit date:
2021-12-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP